MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

This is a multipart, open-label, multi-center dose escalation, dose expansion phase I clinical trial designed to evaluate the safety, tolerability, maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and preliminary efficacy of MEM-288 in patients with advanced solid tumors. Eligible subjects must have a tumor lesion(s) which is accessible for injection. The dose escalation phase (Part 1A - advanced solid tumors) has completed and is closed to enrollment. This phase evaluated multiple doses of MEM-288 dosed via intratumoral injection once every 3 weeks to assess safety, tolerabilit

Trial Details

NCT ID

NCT05076760

Phase

PHASE1

Sponsor

Memgen, Inc.

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Locations (sample)

• Tampa, Florida, United States|27.94752,-82.45843
• Durham, North Carolina, United States|35.99403,-78.89862

Key Eligibility Criteria

• Ability to understand and provide informed consent.
• Willingness and ability to comply with scheduled study visits and procedures.
• Adult men or women age ≥ 18 years.
• ECOG performance status of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →